Current medical management of chronic stable angina

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2004, Pages

  Thadani, Udho ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary artery revascularization; Metabolic modulators; Pharmacologic treatment; Stable angina

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; DILTIAZEM; FELODIPINE; GLYCERYL TRINITRATE; LABETALOL; METOPROLOL; NADOLOL; NICORANDIL; NIFEDIPINE; NITRIC ACID DERIVATIVE; OXPRENOLOL; PINDOLOL; PROPRANOLOL; RANOLAZINE; TIMOLOL; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL; ZATEBRADINE;

ASTHENIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; COUNTERPULSATION; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; ERECTILE DYSFUNCTION; FATIGUE; GENE THERAPY; HEADACHE; HEART INFARCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SPINAL CORD STIMULATION; STABLE ANGINA PECTORIS; SYNCOPE; TORSADE DES POINTES; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VISUAL DISORDER; VIVID DREAM;

EID: 4944236948     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900103     Document Type: Review

References (180)

1. Heberden W. Some account of a disorder of the breast. Med Trans R Coll Phys 2:59, 1772
2. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 9:73-88, 1991
3. Thadani U. Stable angina pectoris. In: Crawford MH, Dimarco JP, eds. Cardiology Mosby 6.1-6.14, 2001
4. Pepine CJ, Abrams J, Mark RA, et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 74:226-231, 1994
5. Asirvatham S, Sebastian C, Thadani U. Choosing the most appropriate treatment for stable angina: Safety considerations. Drug Saf 19:23-44, 1998
6. Braunwald E, Sobel B. Coronary blood flow and myocardial ischemia. In: Braunwal E, ed. Heart disease: A textbook of cardiovascular medicine. Philadelphia: WB Saunders, pp. 1191-1221, 1988
7. Thadani U, Olson EG, Hamilton SF. Pathophysiology of myocardial ischemia. In: Abrams J, Pepine CE, Thadani U eds. Medical therapy of ischemic heart disease. Nitrates, beta-blockers and calcium antagonists. Boston: Little Brown, pp. 1-36, 1992
8. Sarnoff SJ, Braunwald E, Welch GH, et al. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol 132:148-156, 1958
9. Thadani U. Management of stable angina pectoris. Prog Cardiovasc Dis 14:349-358, 1999
10. Davies MJ, Thomas AC. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 53:363-368, 1985
11. Thadani U, Chohan A. Chronic stable angina pectoris: Strategies for effective drug therapy. Postgrad Med 98:175-188, 1995
12. Gage JE, Jess DM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: Reversibility by nitroglycerin. Circulation 73:865-871, 1986
13. Thadani U. The Pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs (suppl 1), pp. 11-20, 2003
14. Hinton TC, Chaitman BR. The prognosis in stable and unstable angina. Cardiol Clin. 9:27-38, 1991
15. Myers J, Prakash M, Partington S, Atwood E. Exercise capacity and instability among men referred for exercise testing. N Eng J Med 346:793-780, 2002
16. Mark DB, Shaw L, Harrell GE, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary disease. N Eng J Med 325:849-853, 1991
17. Dagianti A, Penco M, Agati L, et al. Stress echocardiography: Comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease. J Am Coll Cardiol 26:18-25, 1995
18. Wackers FJTH, Soufer R, Zaret BL. Nuclear cardiology. In: Braunwald E, ed. Heart disease: A textbook of cardiovascular medicine. Philadelphia: WB Saunders pp. 273-359, 1997
19. Thadani U. Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol 79:24-30, 1997
20. Task Force of the European Society Cardiology: Management of stable angina pectoris: Recommendations of the Task Force of the European Society Cardiology. Eur Heart J 18:394-413, 1997
21. Canadian Cardiovascular Society 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 14(Suppl C):1c-23c, 1998
22. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/ AHA/ACP-ASIM Guideline update for the management of patients with chronic stable angina: summary and abstract. Circulation 107:143-158, 2003
23. Yusuf S, Zucker D, Peducci P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of ten year results from randomized trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 344:563-570, 1994
24. Peduzzi P, Kamina A, Detre K, for the VA Coronary Artery Bypass Surgery Cooperative Study Group. Twenty-two-year follow-up in the VA cooperative study of coronary artery bypass surgery for stable angina. Am J Cardiol 81:1393-1399, 1998
25. Hartigan PM, Giacomini JC, Folland ED, Parisi A, for VA Cooperative Studies Program ACME Investigators. Two-to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Am J Cardiol 82:1445-1450, 1998
26. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927-1936, 1999
27. Thadani U, Opie LH. Nitrates. In: Opie LH, ed. Drugs for the heart, 4th ed. Philadelphia: WB Saunders, pp. 31-48, 1995
28. Thadani U, Lipicky RJ. Short and long acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 8:611-623, 1994
29. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 8:625-633, 1994
30. Thadani U. Nitrate tolerance, rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 10:735-742, 1996
31. Thadani U, Fung HL, Darke AL, Parker JO. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose response relationship during acute and sustained therapy. Am J Cardiol 49:411-419, 1982
32. Parker JO, Van Koughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris. Am J Coll Cardiol 54:8-13, 1984
33. De Mots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cordiol 13:786-792, 1989
34. Thadani U, Sharma B, Meeran MD, et al. Comparison of adrenergic beta-receptor antagonists in angina pectoris. BMJ 1:138-142, 1973
35. Thadani U, Davidson C, Simpleton W, Taylor SH. Comparison of the immediate effects of five beta adrenoceptor blocking drugs with different ancillary properties in angina pectoris. N Engl J Med 300:750-755, 1979
36. Opie LH, Sonnenblick EH, Frishman W, Thadani U. Beta blocking agents. In: Opie LH, ed. Drugs for the heart. Philadelphia: WB Saunders pp. 1-27, 1995
37. Thadani U. Assessment of optimal' beta-blockade in treating patients with angina pectoris. Acta Med Scand 694(Suppl):179-187, 1985
38. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 38:273-290, 1996
39. Thadani U. Selective L-Type, and non-selective calcium channel blockers for stable angina pectoris (editorial). Am Heart J 144:8-10, 2002
40. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcomes in patient with chronic stable angina. Eur Heart J 17:104-112, 1996
41. Thadani U, Glasser S, Bittar N, et al. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 74:9-17, 1994
42. Rehnquist N, Hjemdahl P, Billing E, et al. Effect of metoprolol versus verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J 17:76-81, 1996
43. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clin Cardiol 21:633-641, 1998
44. Frishman W, Glasser S, Stone P, et al. Comparison of controlled onset, extended release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 83:507-514, 1999
45. Shapiro W, Dibianco R, Thadani U. Comparative efficacy of 200, 300, and 400 mg of bepridil for chronic, stable angina pectoris. Am J Cardiol 55:36C-42C, 1985
46. Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The bepridil Collaborative Study Group. Am J Cardiol 68:306-312, 1991
47. Frishman WH, Crawford MW, Dibianco R, et al. Combination propranolol-bepridil therapy in stable angina pectoris. Am J Cardiol 55:43C-49C, 1985
48. Thadani U. Combination therapy. Am Coll Cardiol Curr J Rev 6:24-25, 1997
49. Dunselman P, van Kempen L, Bouwens L, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 81:128-132, 1998
50. Knight C, Fox K. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 81:133-136, 1998
51. Strauss WE, Parisi AF. Combined use of calcium channel and beta blockers for the treatment of stable angina, rationale, efficacy and adverse events. Ann Intern Med 109:570-575, 1988
52. Akhras F, Jackson A. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 338:1036-1039, 1991
53. Tolins M, Weir EK, Chesler E, Pierpont GL. Maximal drug therapy is not necessarily optimal in chronic angina pectoris. Am Coll Cardiol 4:1051-1057, 1984
54. Meany JB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 63:66J-70J, 1989
55. Thadani U, Strauss W, Glasser SP, et al. Evaulation of antianginal and anti-ischemic efficacy of nicorandil: Results of a multicenter study. J Am Coll Cardiol 23:276A, 1994
56. Rajarathan R, Brieger D, Hawkins R, Friedman S. An evaluation of anti-ischemic efficacy during therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 83:1120-1124, 1999
57. Opie LH, King LM. Glucose and glycogen utilization in myocardial ischemia-changes in metabolism and consequences for the myocyle. Mol Cell Biochem 180:3-26, 1998
58. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Cardiovasc Res 33:243-257, 1997
59. Taegtmeyer H. Energy substrate metabolism as target for pharmacotherapy in ischemic and repurfused heart muscle. Heart and Metabolism 1:5-9, 1998
60. Lopaschuk GD. Optimizing cardiac energy metabolism: A new approach to treating ischemic heart disease. Eur Heart J Supplement 1(Suppl O):O32-O39, 1999
61. Schwartz GG, Greyson C, Wisneski JA, Garcia J. Inhibition of fatty acid metabolism alters myocardial high energy phosphates in vivo. Am J Physiol 267:H224-H231, 1994
62. Meehan AG, Higgins AJ. Oleate plus oxfenicine improves functional recovery assessed via an intraventricular balloon, in ischemic reperfused rat hearts. Ann NY Acad Sci 723:343-344, 1994
63. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 30:A112, 1998
64. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normaxic, ischemic, and reperfused ischemic rate hearts. Circulation 93:135-142, 1996
65. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain ketoacyle coenzyme A thiolase. Circ Res 86:580-588, 2000
66. Mehrotra TN, Bassadone ET. Trimetazidine in the treatment of angina pectoris. Br J Clin Prac 21:553-554, 1967
67. Brodbin P, O'Conner CA. Trimetazidine in the treatment of angina pectoris. Br J Clin Prac 22:395-396, 1968
68. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induces angina. Controlled multicenter double blind versus placebo study. Arch Mal Coeur Vaiss 79:1331-1336, 1986
69. Sellier P, Audouin P, Payen B, Duong TC, Ourbak P. Ergometric effects of a single administration of trimetazidine. Presse Med 15:1771-1774, 1986
70. Passerson J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study. Presse Med 15:1775-1778, 1986
71. Gallet M. Clinical effectiveness of trimetazidine in stable effort angina. A double-blind versus placebo-controlled study. Presse Med 15:1779-1782, 1986
72. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: A new concept in the treatment of angina. Br J Clin Pharmacol 37:279-288, 1994
73. Dalla-Volta S, Maraglino G, Della-Valentinea P, Viena P, Desideri A. Comparison of trimetazidine with nefedipine in effort angina: A double-blind crossover study. Cardiovasc Drugs Ther 4(Suppl 4):853-859, 1990
74. Levy S, Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 76:353-357, 1997
75. Michaelides AP, Vyssoulis GP, Bonoris PB. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Therapeut Res 46:1179-1190, 1989
76. Michalides AP, Spiropoulos K, Dimopoulos K, et al. Anti-anginal efficacy of the combination of trimetazidine-proprandolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 13:8-14, 1997
77. Chierchia SL, Fragasso G. Protective effects of trimetazidine on ischemic myocardial dysfunction. Eur Heart J Supplement 1(Suppl O):O24-O27, 1999
78. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Eur Heart J 22:2267-2274, 2001
79. Sellier P, Brounstet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris. A multicenter, double blind, placebo controlled study. Am J Cardiovasc Drugs 3(s):361-369, 2003
80. Aaker A, McCormack JG, Hirai T, et al. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 28(3):353-362, 1996
81. Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect on ischemic myocardium. Eur J Clin Pharmacol 38(2):111-114, 1990
82. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 20(1):131-138, 1992
83. Thadani U, Ezekowitz M, Fenney L, et al. Double-blind efficacy and safety study of a novel anti-ischemic agnet, ranolazine, versus placebo in patients with chronic stable angina pectoris; Ranolazine Study Group. Circulation 30(2):726-734, 1994
84. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional anti-anginal agents. Am J Cardiol 84(1):46-50, 1999
85. Chaitman BR, Skettino SL, Parker JO, for the monotherapy assessment of ranolazine in stable angina (MARISA) Investigators. Anti-ischemic and long term survival during ranolazine monotherapy in patients with severe chronic stable angina. J Am Coll Cardiol 43:1375-1382, 2004
86. Chaitman BR, Pepine J, Parker JO, for the CLARISA Study Group. Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291:309-316, 2004
87. Glasser SP, Michie DD, Thadani U, et al. For the zatebradine investigators. Effects of zatebradine (ULFS/USCL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina. Am J Cardiol 79:1401-1404, 1997
88. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: Results of a multicenter, randomized double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J Am Coll Cardiol 26(2):305-312, 1995
89. Borer JS, Fox K, Jaillon P, et al for the Ivabradine Investigators group. Anti-anginal and anti-ischemic effects of Ivabradine, an If inhibitor, in stable angina. Circulation 107:817-824, 2003
90. Pepine CJ, Rouleau JL, Annis K, et al. Effect of angiotensin converting enzyme inhibitor on transient ischemia: The Quinapril anti-ischemia and symptoms of angina reduction. (QUASAR) trial. J Am Coll Cordiol 42:2043-2059, 2003
91. Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the bypass angioplasty revascularization investigation (BARI) randomized trial. Circulation 96:2162-2170, 1997
92. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the prevention of restenosis with Tranilast and its outcomes (PRESTO) trial. Circulation 103:476-480, 2004
93. Henderson RA, et al. For the randomized intervention treatment of angina trial participants. Seven-year outcome in the RIATA -2 trial. Coronary angioplasty versus medical therapy. J Am Coll Cardiology 42:1167-1170, 2003
94. King SR III. Dilate or defer? View of a skeptic. J Am Coll Cardiol 42:1171-1172, 2003
95. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with standard stent for coronary revascularization. N Engl J Med 346: 1773-1780, 2002
96. Mosses JW, Leon MB, Pompa JJ, et al. Sirolimus-eluting stents versus standard stents in patients with a native coronary artery. N Engl J Med 349:1315-1324, 2003
97. Shofer J, Schluter M, Gershlick AH, et al. For the E-SIRUS sirolimus-eluting stents for the treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomized controlled trial. (E-SIRUS). Lancet 362:1093-1099, 2003
98. Ellis S, Stone W, Pompa JJ, et al. The TAXUS IV study: Final angiographic results 108(Suppl IV):IV-532, 2003
99. Le Mos PM, Serruys PW, Vandomburg RJ, et al. Unrestricted utilization or sirolimus-eluting stents compared with conventional bare stents implantation in the "real world" the rapamycin eluting stents evaluated at Rotterdam Cardiology Hospital (Research) Registry. Circulation 109:190-195, 2004
100. Faxon DP. Bringing reality to drug-coated stents. Circulation 109:140-142, 2004
101. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 341:70-76, 1999
102. Muneretto C, Bisleri G, Negri A, et al. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: A prospective randomized comparison with conventional coronary artery bypass surgery. Circulation 108:1129-1133, 2003
103. Doll R, Peto R. Mortality in relation to smoking: 20-year observations on British doctors. BMJ 2:1526-2536, 1976
104. SAPAT (Swedish Angina Pectoris Aspirin Trial) Group, Juul-Moller S, Edvardson N, Jahnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 340:1421-1425, 1992
105. Food and Drug Administration. Acetylsalicyclic acid and the heart. JAMA 270:2669, 1993
106. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659-675, 1993
107. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001
108. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
109. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of artherosclerosis. J Am Coll Cardiol 35:1-10, 2000
110. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high risk individuals. A randomized placebo controlled trial. Lancet 36:7-22, 2003
111. Rubins HB, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
112. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 3:30-35, 2004
113. Imhof A, Koenig W. Alcohol inflammation and coronary heart disease. Addiction Biology 8:271-277, 2003
114. Pepine C. Rationale for ACE inhibition as anti-ischemic therapy. Eur Heart J 19:G34-G40, 1998
115. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 527:669-677, 1992
116. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325:293-302, 1991
117. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
118. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Investigators. Efficacy of perindopril in reduction of cardiovascular events among patietns with stable coronary artery disease: randomized, double-blind, placebo controlled, multicenter trial (The EUROPA study) Lancet 2003 (Sept 1) published on-line.
119. Pfeffer MA, et al for the PEACE Investigators. The continuation of the prevention of events with angiotensin-converting enzyme inhibition (PEACE) trial. Am Heart J p. 142, 2001
120. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the post infarction period. Am J Cardiol 80(9B):35J-39J, 1997
121. MERIT-HF Study Group. Effect of metoprolol Cx/xL in chronic heart failure. Metoprolol Cx/CL, randomized international trial in congestive heart failure (MERIT HF) Lancet 353:2001-2007, 1999
122. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Jeart Failure Study Group. N Engl J Med 33:1349-1355, 1996
123. CIBIS II Investigators. The cardiac insufficiency bisoprolol study (CIBIS II) A randomized trial. Lancet 353:9-13, 1999
124. Pepine CJ, Cohn PF, Deedwania P, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The atenolol silent ischemia study (ASIST). Circulation 90:762-768, 1994
125. Davis R, Goldberg A, Forman S, Pepine C, et al. Asymptomatic cardiac ischemia pilot (ACIP) study two year follow up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95:2037-2043, 1997
126. The IONA study group. Effect of nicorandil on coronary events in patients with stable angina: The impact of nicorandil in angina (IONA) randomized trial. Lancet 35S: 1265-1279, 2003
127. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (JNCVII). Hypertension 43(1):1-3, 2004
128. ALLHAT officers and coordinators for the ALLHAT collaborative group. Major outcomes in high risk hypertensive patients. Randomized angiotensin-converting enzyme inhibitor, calcium channel blocker vs. diuretic. The antihypertensive and lipid lowering treatment to prevent hart attack trial (ALLHAT). JAMA 288:2981-2987, 2002
129. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. J Am Coll Cardiol 39:923-934, 2002
130. Thadani U. Patient with disabling angina not amenable to revascularization procedures in acute coronary syndromes: A comparison to Braunwald's heart disease. P. Theroux Ed. Saunders pp. 535-552, 2003
131. Lawson WE, Hui JC, Zheng ZS, et al. Improved exercise tolerance following enhanced external counterpulsation: Cardiac or peripheral effect? Cardiology 87:271-275, 1996
132. Masuda D, Nohara R, Hirai T, et al. Enhanced external counterpulsation improved myocardial perfusion and coronary flow reserve in patients with chronic stable angina; evaluation by (13) N-ammonia positron emission tomography. Eur Heart J 22(16):1451-1458, 2001
133. Schecter M, Matotzky P, Feinberg S, et al. Enhanced counter pulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol 42:2090-2095, 2003
134. Arora R, Chou T, Jain D, et al. The Multicenter Study of Enhanced External CounterPulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 33:1833-1840, 1999
135. Lawson WE, Hui JC, Cohn PF. Long-term prognosis of patients with angina tratment with enhanced external counterpulsation: Five-year follow-up study. Clin Cardiol 23:254-258, 2000
136. Barsness G, Feldman AM, Holmes DR, et al. The International EECP Patient Registry (IEPR): Design, methods, baseline characteristics, and acute results. Clin Cardiol 24:435-442, 2001
137. Bueno EA, Mamtani R, Frishman WH. Alternative approaches to the medical management of angina pectoris. Acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Disease 3:236-241, 2001
138. Chester M, Hammond C, Leach A. Transcutaneous electrical stimulation in severe angina pectoris. Eur Heart J 3:297-302, 1982
139. Mannheimer C, Carlsson CA, Emanuelson H, et al. The effects of transcutaneous electric stimulation in patients with severe angina pectoris. Circulation 71:308-316, 1985
140. Mannheimer C, Carlsson CA, Vedin A, Wilhelmsson C. Transcutaneous electrical nerve stimulation (TENS) in angina pectoris. Pain 26:291-300, 1986
141. Mannheimer C, Emanuelsson H, Waagstein F, Wilhemsson C. Influence of naloxone on the effects of high frequency transcutaneous electrical nerve stimulation in angina pectoris induced by atrial pacing. Br Heart J 62:36-42, 1989
142. Magarian GJ, Leikam B, Palac R. Transcutaneous electrical nerve stimulation (TENS) for treatment of severe angina pectoris refractory to maximal medical and surgical management - a case report.. Angiology 41:408-411, 1990
143. Murphy DF, Giles KE. Dorsal column stimulation for pain relief from intractable angina pectoris. Pain 28:365-368, 1987
144. Mannheimer C, Augustinsson LE, Carlsson CA, et al. Epidural spinal electrical stimulation in severe angina pectoris. Br Heart J 49:46-61, 1988
145. Sanderson JE, Brooksby P, Waterhouse D, et al. Epidural spinal electrical stimulation for severe angina: A study of its effects on symptoms, exercise tolerance and degree of ischaemia. Eur Heart J 13:628-633, 1992
146. Harke H, Ladleif HU, Rethage B, Grosser KD. Epidural spinal cord stimulation in therapy-resistant angina pectoris. Anaesthesist 42:557-563, 1993
147. Mannheimer C, Augustinsson LE, Eliasson T. Spinal cord stimulation in severe angina pectoris. Reduced ischemia and increased quality of life. Lakartidningen 91:3257-3261, 1994
148. Jacques L, Napoleon MS, Gagnon RM, et al. Epidural stimulation in the treatment of refractory angina. Annales de Chirurgie 48:764-767, 1994
149. Hautvast RW, DeJongste MJ, Staal MJ, et al. Spinal cord stimulation in chronic intractable angina pectoris: A randomized, controlled efficacy study. Am Heart J 137:1114-1120, 1998
150. Hautvast RWM, Brower J, DeJonste MJL, Lie KI. Effect of spinal cord stimulation on heart rate variability and myocardial ischemia in patients with chronic intractable angina pectoris: A prospective ambulatory electrocardiographic study. Clin Cardiol 21:33-38, 1998
151. Greco S, Auriti A, Fiume D, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: A two-year follow up. Pacing Clin Electrophysiol 22:26-32, 1999
152. Norrsell H, Eliasson T, Augustinsson LE, Mannheimer C. Spinal cord stimulation in angina pectoris - what is the current situation? Lakartidningen 96:14302,1435-1437, 1999
153. Barolat G, Sharan AD. Future trends in spinal cord stimulation. 22:279-284, 2000
154. Latif OA, Nedeljkovic SS, Stevenson LW. Spinal cord stimulation for chronic intractable angina pectoris: A unified theory on its mechanism. Clin Cardiol 24:533-541, 2001
155. Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery is severe angina pectoris: The ESBY study. Circulation 37:1157-1163, 1998
156. Murray S, Collins PD, James MA. Neurostimulation treatment for angina pectoris. Heart 83:217-220, 2000
157. Wearn JT, Mettier SR, Klumpp TG, et al. The nature of the vascular communications between the coronary arteries and the chambers of the heart. Am Heart J 9:143-164, 1933
158. Okada M, Ikuta H, Shimizu K, et al. Alternative method of myocardial revascularization by laser: Experimental and clinical study. Kobe J Med Sci 32:151-161, 1986
159. Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: Results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 113:645-654, 1997
160. Cherian SM, Bobryshev YV, Liang H, et al. Ultrastructural and immunohistochemical analysis of early myocardial changes following transmyocardial laser revascularization. J Car Surg 15:341-346, 2000
161. Al-Sheikh T, Allen KB, Straka SP, et al. Cardiac sympathetic denervation after transmyocardial laser revascularization. Circulation 100:135-140, 1999
162. Lange RA, Hillis LD. Transmyocardial laser revascularization. N Engl J Med 341:1074-1076, 1999
163. Burns SM, Sharples LD, Tait S, Cain N, Wallwork J, Schofield PM, et al. The transmyocardial laser revascularization international registry report. Eur Heart J 20:31-37, 1999
164. 2 laser. Circulation 18:104(Suppl 1)1-4, 2001
165. Schofield PM, Sharples LD, Caine N, et al. Transmyocardial laser revascularization in patients with refractory angina: A randomized controlled trial. Lancet 353:519-524, 1999
166. Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 341:1021-1028, 1999
167. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 341:1029-1036, 1999
168. Burkoff D, Schmidt S, Schulman SP, et al. The Angina Treatments-Lasers and Normal Therapies In Comparison Investigators (ATLANTIC). Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomized trial. Lancet 354:885-890, 1999
169. Hughes GC, Landolfo KP, Lowe JE, Coleman RB, Donovan CL. Perioperative morbidity after transmyocardial laser revascularization: Incidence and risk factors for adverse events. J Am Coll Cardiol 33:1021-1026, 1999
170. Leon MB, Bain DS, Moses JW, et al. Direct laser myocardial revascularization with BiosenseTM LV electromechanical mapping in patients with refractory myocardial ischemia. Final results of a blind randomized clinical trial. JACC 38:595-596, 2001
171. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularization for severe angina: The Potential Class Improvement From Intramyocardial Channels (PACIFIC) randomized trial. Lancet 356:1705-1710, 2000
172. Stone GSW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous laser revascularization in patients with non-recanalizable ostial occlusions. J Am Coll Cardiol 39:1581-1587, 2002
173. Henry TD, Annex, BH, Azrin MA, et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 100(suppl):I-476, 1999
174. Simons M, Annex BH, Laham RJ, et al. Pharmacologist treatment of coronary artery disease with recombinant fibroblast growth factor-2 (rFGF-2): Double-blind, randomized controlled clinical trial. Circulation 2002, in press.
175. Ware JA. Too many vessels? Not enough? The wrong kind? The VEGF debate continues. Nature Med 7:425-429, 2001
176. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142:972-980, 2001
177. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy. Amidst the hype, the reflected potential for serious side effects. Circulation 104:115-119, 2001
178. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297, 2002
179. Thadani U. Recurrent and refractory angina following revascularization procedures in patients with stable angina. Editorial. Coronary Artery Disease 15(Suppl 1):S1-S4, 2004
180. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation 109:1371-1378, 2004